Hikma Pharmaceuticals Share News (HIK)

IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.

Hikma gets preliminary approval from US FTC for Custopharm deal

(Sharecast News) - Hikma Pharmaceuticals has received preliminary approval from the US Federal Trade Commission for the acquisition of sterile injectables company Custopharm Inc from Water Street Healthcare for up to $425m.

LONDON BROKER RATINGS: JPMorgan lowers Rolls-Royce; UBS likes Ryanair

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

UK dividends calendar - next 7 days

LONDON BROKER RATINGS: Downgrades for Hikma Pharma and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

LONDON BRIEFING: LSEG says Refinitiv savings bigger, ahead of schedule

(Alliance News) - London Stock Exchange Group on Thursday said 2021 was a successful year following the acquisition of Refinitiv, leaving the stock exchange operator well positioned as a financial market infrastructure and data business.

LONDON BROKER RATINGS: Downgrades for AB Foods, BT and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

IN BRIEF: Hikma Pharmaceuticals launches first phase of share buyback

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase will begin on Friday and end by June 25. Hikma had announced the buyback programme with its annual results, saying it reflected its strong cash generation, balance sheet strength, and confidence in future growth prospects. Hikma also had declared a final dividend of 36 cents, a 5.9% boost from a shareholder payout of 34 cents the year before. Its full-year dividend amounted to 54 US cents, up 8.0% from 50 cents.

LONDON BRIEFING: IAG expects to fly 85% of pre-virus capacity in 2022

(Alliance News) - International Consolidated Airlines Group on Friday posted a narrowed loss for 2021, saying that after the setback caused by Omicron at the end of the year, bookings have rebounded strongly and it expects to fly 85% of its 2019 capacity in 2022.

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

UK earnings, trading statements calendar - next 7 days

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets